A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer

Published:2014-03 Issue:2 Volume:15 Page:96-102
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Sekine Ikuo,Okamoto Hiroaki,Horai Takeshi,Nakagawa Kazuhiko,Ohmatsu Hironobu,Yokoyama Akira,Katakami Nobuyuki,Shibuya Masahiko,Saijo Nagahiro,Fukuoka Masahiro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Trends in lung cancer incidence by histological type in Osaka, Japan.;Toyoda;Jpn J Clin Oncol,2008

2. Small-cell lung cancer;van Meerbeeck;Lancet,2011

3. Treatment of small-cell lung cancer in elderly patients;Pallis;Cancer,2010

4. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702;Okamoto;Br J Cancer,2007

5. Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin;Yamamoto;Drug Des Devel Ther,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statistical Analysis Methods and Reporting of Patient-Reported Outcomes in Randomized Controlled Trials for Cancer Conducted in Japan: A Systematic Review;Cureus;2024-05-21

2. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline;Journal of Clinical Oncology;2023-12-10

3. Symptom Management;The Role of the Clinical Nurse Specialist in Cancer Care;2023-09-05

4. A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer;Clinical Lung Cancer;2023-06

5. Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study;International Journal of Clinical Oncology;2023-05-12